Fazamorexant

A dual orexin receptor antagonist used for insomnia

Fazamorexant
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Fazamorexant is a medication that acts as a dual orexin receptor antagonist (DORA). It is primarily used in the treatment of insomnia, a condition characterized by difficulty falling asleep or staying asleep.

Mechanism of Action

Fazamorexant works by selectively blocking the action of orexin neuropeptides. Orexins, also known as hypocretins, are neuropeptides that regulate arousal, wakefulness, and appetite. By inhibiting the binding of orexins to their receptors, Fazamorexant reduces wakefulness and promotes sleep.

Pharmacology

Fazamorexant is designed to target both orexin receptor subtypes, OX1R and OX2R. This dual antagonism is believed to contribute to its effectiveness in promoting sleep without the sedative side effects commonly associated with other sleep aids, such as benzodiazepines or non-benzodiazepine hypnotics.

Clinical Use

Fazamorexant is indicated for the treatment of insomnia in adults. It is particularly useful for patients who have difficulty maintaining sleep throughout the night. The medication is typically administered orally, and its effects can be observed within a few hours of ingestion.

Side Effects

Common side effects of Fazamorexant may include drowsiness, headache, and dizziness. As with other sleep medications, there is a potential for next-day drowsiness, which can affect activities that require full alertness, such as driving.

Development and Approval

Fazamorexant was developed as part of ongoing research into orexin receptor antagonists as a novel approach to treating sleep disorders. It represents a shift from traditional sedative-hypnotics to a mechanism that more directly targets the sleep-wake cycle.

Related Pages

• Insomnia
• Orexin receptor
• Dual orexin receptor antagonist
• Sleep disorder